Fractyl Health's Revita procedure shows promise in maintaining weight after stopping GLP-1 drugs, with new six-month data prompting the company to seek a streamlined FDA pathway. A packed 2026 roadmap aims for a U.S. submission, but financial pressures loom.
SAP discontinues its legacy IS-H healthcare software in the DACH region, impacting dozens of hospitals, while appointing David Robinson to lead its crucial North American operations. The moves signal a strategic pivot as the enterprise software giant navigates a complex market landscape.
Consumer goods giant Procter & Gamble has agreed to acquire Wonderbelly, a fast-growing brand in the 'free-from' digestive health space, signaling a deeper push into the lucrative wellness category and a bid to attract younger, label-conscious consumers.
Cardinal Health (CAH) stock has drawn renewed investor interest following robust financial results, with revenue topping $234 billion and net income near $1.6 billion. The healthcare distributor's shares have rallied over 66% in the past year, though its premium valuation compared to peers is sparking debate among analysts.
Facing uneven long-term performance, UPS announces a major strategic overhaul involving significant job reductions, facility closures, and a deliberate move away from low-margin Amazon volume. The company is betting big on healthcare logistics through acquisitions to bolster its global cold chain network.
The U.S. government's $1.6 billion commitment to USA Rare Earth signals a strategic pivot towards fostering competition in the critical minerals sector, reducing price supports and introducing new volatility. As policy shifts, industry leader MP Materials counters with record production and expanded magnet manufacturing, highlighting the intensifying race to secure a domestic supply chain for EVs and defense.
Despite a 5% share price gain over the last quarter, a deep dive into Fevara plc's (LON:FVA) fundamentals reveals concerning trends. With a declining net income and a high dividend payout strategy stifling reinvestment, analysts question the sustainability of its current valuation.
Health and Human Services Secretary Robert F. Kennedy Jr. has publicly addressed the deep divisions within America's most storied political family, following the death of his cousin Tatiana Schlossberg and amidst ongoing policy controversies that have placed him at odds with his relatives.
Bitcoin plunged to a nine-month low as a confluence of political uncertainty and geopolitical tensions sparked a broad market sell-off, forcing over $1.6 billion in leveraged positions to close.
The medtech giant inaugurates a Centre of Excellence in Swords, aiming to accelerate development of its Atellica diagnostic systems and bolster Ireland's life sciences sector amid strategic corporate shifts.
As a federal judge advances a lawsuit tying Bank of America to Jeffrey Epstein's sex trafficking network, the financial giant simultaneously positions itself at the forefront of stablecoin regulation discussions with Coinbase and the White House, creating a complex risk-and-opportunity landscape for investors.
The European Central Bank convenes this week with a resurgent euro presenting a fresh dilemma, threatening to dampen inflation and undermine the export engine of the eurozone's largest economies just as recovery gains momentum.
U.S. stocks extended losses into a third session as investors weighed the potential implications of Kevin Warsh's nomination to lead the Federal Reserve, capping a volatile week of trading.
As Jerome Powell prepares to hand over the reins, his public counsel to a successor underscores the delicate balance between central bank independence and democratic accountability. With Kevin Warsh named as his replacement, the Fed may be poised for a significant shift in philosophy and approach.
A week of significant stock swings saw Lockheed Martin and Texas Instruments surge on strong outlooks, while Humana plunged on regulatory headwinds. Here’s what drove the action and what analysts are saying.
Medical device maker ResMed (RMD) reported fourth-quarter revenue of $1.42 billion, an 11% year-over-year increase that surpassed Wall Street forecasts. Non-GAAP earnings per share reached $2.81, also topping analyst expectations.
Guggenheim Securities has initiated coverage of clinical-stage biopharma AtaiBeckley with a Buy rating and an $11 price target, highlighting its leadership in next-generation psychiatric treatments following its merger with Beckley Psytech.
After a punishing year of underperformance and operational setbacks, Baxter International faces a skeptical analyst community. While some see deep value, the consensus remains firmly on hold as the company navigates product challenges and revised guidance.
St. Louis Fed President Alberto Musalem argues the current interest rate stance is appropriate, signaling a pause in the central bank's easing cycle unless the labor market weakens or inflation drops unexpectedly.
A U.S. license shift paves the way for Chevron to expand its unique position in Venezuela's oil sector, offering potential upside amid significant political and operational risks.
